{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:13:44Z","timestamp":1779106424937,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109091","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:24:46Z","timestamp":1779103486000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Adalimumab in Retinitis Pigmentosa: A Prospective Pilot Study Assessing Ocular Safety and Feasibility"],"prefix":"10.7759","author":[{"given":"Rubens C","family":"Siqueira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tainara S","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinara C","family":"Brandao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"18","author":"Hartong DT","year":"2006","unstructured":"Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006, 18:1795-809. 10.1016\/S0140-6736(06)69740-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.08.001","article-title":"Corrigendum to molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspective progress in retinal and eye research (2018) Vol 63,107-131","volume":"66","author":"Dias MF","year":"2018","unstructured":"Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, Kwon YJ. Corrigendum to molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspective progress in retinal and eye research (2018) Vol 63,107-131. Prog Retin Eye Res. 2018, 66:220-1. 10.1016\/j.preteyeres.2018.08.001","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-221","article-title":"Small interfering RNA-mediated suppression of Ccl2 in M\u00fcller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration","volume":"9","author":"Rutar M","year":"2012","unstructured":"Rutar M, Natoli R, Provis JM. Small interfering RNA-mediated suppression of Ccl2 in M\u00fcller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration. J Neuroinflammation. 2012, 9:221. 10.1186\/1742-2094-9-221","journal-title":"J Neuroinflammation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071724","article-title":"The role of cytokines in degenerative retinal diseases: a comprehensive review","volume":"13","author":"Siqueira RC","year":"2025","unstructured":"Siqueira RC, Brand\u00e3o CC. The role of cytokines in degenerative retinal diseases: a comprehensive review. Biomedicines. 2025, 13:10.3390\/biomedicines13071724","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110024","article-title":"Interleukin-1\u03b2 induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes","volume":"9","author":"Wang Y","year":"2014","unstructured":"Wang Y, Jin S, Sonobe Y, et al.. Interleukin-1\u03b2 induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. PLoS One. 2014, 9:e110024. 10.1371\/journal.pone.0110024","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505298","article-title":"Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration","volume":"7","author":"Zhao L","year":"2015","unstructured":"Zhao L, Zabel MK, Wang X, et al.. Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration. EMBO Mol Med. 2015, 7:1179-97. 10.15252\/emmm.201505298","journal-title":"EMBO Mol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11061086","article-title":"Inherited retinal dystrophies: role of oxidative stress and inflammation in their physiopathology and therapeutic implications","volume":"11","author":"Pinilla I","year":"2022","unstructured":"Pinilla I, Maneu V, Campello L, et al.. Inherited retinal dystrophies: role of oxidative stress and inflammation in their physiopathology and therapeutic implications. Antioxidants (Basel). 2022, 11:10.3390\/antiox11061086","journal-title":"Antioxidants (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.006","article-title":"Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa","volume":"120","author":"Yoshida N","year":"2013","unstructured":"Yoshida N, Ikeda Y, Notomi S, et al.. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013, 120:100-5. 10.1016\/j.ophtha.2012.07.006","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.08.004","article-title":"The mechanism of cone cell death in retinitis pigmentosa","volume":"62","author":"Campochiaro PA","year":"2018","unstructured":"Campochiaro PA, Mir TA. The mechanism of cone cell death in retinitis pigmentosa. Prog Retin Eye Res. 2018, 62:24-37. 10.1016\/j.preteyeres.2017.08.004","journal-title":"Prog Retin Eye Res"},{"key":"ref10","article-title":"Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts","volume":"7","author":"Mirshahi A","year":"2012","unstructured":"Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H.. Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J. Ophthalmic Vis. Res. 2012, 7:39-44.","journal-title":"J. Ophthalmic Vis. Res"},{"key":"ref11","article-title":"Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts","volume":"7","author":"Mirshahi A","year":"2012","unstructured":"Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H. Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res. 2012, 7:39-44.","journal-title":"J Ophthalmic Vis Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0174","article-title":"Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit","volume":"27","author":"Manzano RP","year":"2011","unstructured":"Manzano RP, Peyman GA, Carvounis PE, et al.. Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther. 2011, 27:327-31. 10.1089\/jop.2010.0174","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2014.898309","article-title":"Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab","volume":"39","author":"Myers AC","year":"2014","unstructured":"Myers AC, Ghosh F, Andr\u00e9asson S, Ponjavic V. Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab. Curr Eye Res. 2014, 39:1106-16. 10.3109\/02713683.2014.898309","journal-title":"Curr Eye Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1065-y","article-title":"Evaluation of potential retinal toxicity of adalimumab (Humira)","volume":"247","author":"Tsilimbaris M","year":"2009","unstructured":"Tsilimbaris M, Diakonis VF, Naoumidi I, et al.. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009, 247:1119-25. 10.1007\/s00417-009-1065-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/25158414221097418","article-title":"A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology","volume":"14","author":"Hasan N","year":"2022","unstructured":"Hasan N, Chawla R, Shaikh N, Kandasamy S, Azad SV, Sundar MD. A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology. Ther Adv Ophthalmol. 2022, 14:25158414221097418. 10.1177\/25158414221097418","journal-title":"Ther Adv Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.990041","article-title":"Intravitreal adalimumab in active noninfectious uveitis: a pilot study","volume":"24","author":"Hamam RN","year":"2016","unstructured":"Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, Mansour AM. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm. 2016, 24:319-26. 10.3109\/09273948.2014.990041","journal-title":"Ocul Immunol Inflamm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2025.2526692","article-title":"Intravitreal versus subcutaneous adalimumab in active non-infectious uveitis: a randomized non-inferiority trial","volume":"34","author":"Hassoun MM","year":"2026","unstructured":"Hassoun MM, Mahfoud ZR, Istambouli R, et al.. Intravitreal versus subcutaneous adalimumab in active non-infectious uveitis: a randomized non-inferiority trial. Ocul Immunol Inflamm. 2026, 34:1-10. 10.1080\/09273948.2025.2526692","journal-title":"Ocul Immunol Inflamm"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1080\/09273948.2017.1335756","article-title":"Intravitreal adalimumab for the control of breakthrough intraocular inflammation","volume":"26","author":"Kheir WJ","year":"2018","unstructured":"Kheir WJ, Mehanna CJ, Abdul Fattah M, Al Ghadban S, El Sabban M, Mansour AM, Hamam RN.. Intravitreal adalimumab for the control of breakthrough intraocular inflammation. Ocul. Immunol. Inflamm. 2018, 26:1206-1211.","journal-title":"Ocul. Immunol. Inflamm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117962","article-title":"Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy","volume":"185","author":"Velasco S","year":"2025","unstructured":"Velasco S, Gallego I, Olivares-Gonz\u00e1lez L, et al.. Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy. Biomed Pharmacother. 2025, 185:117962. 10.1016\/j.biopha.2025.117962","journal-title":"Biomed Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000044RR","article-title":"Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice","volume":"34","author":"Olivares-Gonz\u00e1lez L","year":"2020","unstructured":"Olivares-Gonz\u00e1lez L, Velasco S, Mill\u00e1n JM, Rodrigo R. Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice. FASEB J. 2020, 34:13839-61. 10.1096\/fj.202000044RR","journal-title":"FASEB J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/srep11764","article-title":"Adalimumab reduces photoreceptor cell death in a mouse model of retinal degeneration","volume":"5","author":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara C","year":"2015","unstructured":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara C, Hern\u00e1ndez-Pinto AM, Olivares-Gonz\u00e1lez L, et al.. Adalimumab reduces photoreceptor cell death in a mouse model of retinal degeneration. Sci Rep. 2015, 5:11764. 10.1038\/srep11764","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2838","article-title":"Emerging therapies for inherited retinal degeneration","volume":"8","author":"Scholl HP","year":"2016","unstructured":"Scholl HP, Strauss RW, Singh MS, Dalkara D, Roska B, Picaud S, Sahel JA. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016, 8:368rv6. 10.1126\/scitranslmed.aaf2838","journal-title":"Sci Transl Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202400494","article-title":"Intravitreal administration of adalimumab-loaded poly(lactic-co-glycolic acid) nanoparticles: effects on biodistribution and pharmacokinetics","volume":"5","author":"Garc\u00eda-Otero X","year":"2025","unstructured":"Garc\u00eda-Otero X, Varela-Fern\u00e1ndez R, Cuartero-Mart\u00ednez A, et al.. Intravitreal administration of adalimumab-loaded poly(lactic-co-glycolic acid) nanoparticles: effects on biodistribution and pharmacokinetics. Small Sci. 2025, 5:2400494. 10.1002\/smsc.202400494","journal-title":"Small Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-014-0026-8","article-title":"Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders","volume":"4","author":"Pascual-Camps I","year":"2014","unstructured":"Pascual-Camps I, Hern\u00e1ndez-Mart\u00ednez P, Monje-Fern\u00e1ndez L, et al.. Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders. J Ophthalmic Inflamm Infect. 2014, 4:26. 10.1186\/s12348-014-0026-8","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487896-intravitreal-adalimumab-in-retinitis-pigmentosa-a-prospective-pilot-study-assessing-ocular-safety-and-feasibility","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:24:47Z","timestamp":1779103487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487896-intravitreal-adalimumab-in-retinitis-pigmentosa-a-prospective-pilot-study-assessing-ocular-safety-and-feasibility"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.109091","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}